Phase 2 Study of Oral Brepocitinib for Systemic Lupus Erythematosus Fails
A Phase 2study to evaluate the oral therapy, brepocitinib, for systemic lupus erythematosus (SLE) failed to meet its primary end point of SLE Responder Index (SRI-4) after 52 weeks. Brepocitinib is a TYK2/JAK1 inhibitor designed to reduce inflammatory responses.
Brepocitinib was tested in adults with moderate to severe SLE. Compared to the placebo, it did not obtain a significant difference in disease activity. While trials for lupus will not continue, the drug shows promising results for other autoimmune and inflammatory diseases, including non-infectious uveitis, psoriasis, ulcerative colitis, and Crohn’s disease; The drug developer will continue research for these conditions.
Continue to follow the Lupus Foundation of America for updates on lupus drug development news and clinical trials. Learn more about medications used to treat lupus.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.